Cendakimab (RPC4046; ABT 308; CC-93538) is a humanized, recombinant monoclonal antibody engineered to selectively target the interleukin-13 (IL-13) cytokine. Demonstrating high affinity and potency, this antibody effectively binds to both the wild-type and variant forms of human IL-13. Cendakimab inhibits the interaction of IL-13 with its receptors, IL-13Rα1 and IL-13Rα2, exhibiting half-maximal inhibitory concentrations (IC50s) of 352 pM and 631 pM, respectively, as determined by enzyme-linked immunosorbent assay (ELISA). Furthermore, it exhibits binding affinities of 52 pM for wild-type IL-13 and 50 pM for the R110Q polymorphic variant of IL-13. The therapeutic potential of Cendakimab spans various IL-13-mediated allergic and inflammatory conditions, including asthma and eosinophilic esophagitis.
Cendakimab (RPC4046; ABT 308; CC-93538) is a humanized, recombinant monoclonal antibody engineered to selectively target the interleukin-13 (IL-13) cytokine. Demonstrating high affinity and potency, this antibody effectively binds to both the wild-type and variant forms of human IL-13. Cendakimab inhibits the interaction of IL-13 with its receptors, IL-13Rα1 and IL-13Rα2, exhibiting half-maximal inhibitory concentrations (IC50s) of 352 pM and 631 pM, respectively, as determined by enzyme-linked immunosorbent assay (ELISA). Furthermore, it exhibits binding affinities of 52 pM for wild-type IL-13 and 50 pM for the R110Q polymorphic variant of IL-13. The therapeutic potential of Cendakimab spans various IL-13-mediated allergic and inflammatory conditions, including asthma and eosinophilic esophagitis.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
Please check COA/MSDS for correct molecular weight.
Calculate the dilution required to prepare a stock solution.This equation is commonly abbreviated as: C1V1 = C2V2
Frequently Asked Questions
What are Biosimilar Antibodies?
Biosimilar antibodies are research-grade recombinant antibodies designed to closely resemble approved therapeutic antibodies in terms of amino acid sequence, structural characteristics, and biological activity. These antibodies are generated using recombinant expression technologies and retain the same variable regions as their corresponding reference therapeutics, thereby preserving target specificity and binding affinity. Owing to these properties, biosimilar antibodies serve as reliable and cost-effective research reagents for applications in drug discovery, pharmacological studies, and basic biomedical research.
Research-grade biosimilar antibodies have been successfully expressed and functionally validated against a wide range of widely studied targets. These antibodies can be directly utilized as positive control reagents in drug discovery programs, as well as reference tools for rapid verification of the biological functions of target proteins in biochemical and cellular assays.
